Effect of Two Different ART Regimens on AIDS Patients With Lymphoma

Abstract

Objective: To explore the impact of two different ART regimens on AIDS patients with lymphoma.

Methods: A retrospective study was carried out involving 60 patients diagnosed with AIDS and lymphoma and treated in our hospital during the period from June 2022 to December 2023. All patients underwent DA-EPOCH chemotherapy. According to the differences in ART treatment regimens, patients receiving the DTG + lamivudine (3TC) regimen will be categorized into the DTG + 3TC group, and patients receiving the TDF + 3TC + efavirenz (EFV) regimen will be classified into the TDF + 3TC + EFV group, with 30 cases in each group. The HIV viral load was compared between the two groups pretreatment and posttreatment (at 12, 24, and 26 weeks). The immunological indices (CD4⁺ and CD8⁺), liver function indices (serum total bilirubin [TBIL], alanine transaminase [ALT], aspartate transaminase [AST], serum albumin [ALB], and prothrombin time [PT]), and blood creatinine (Scr) levels of the two groups were compared before and after treatment (at 36 weeks). The occurrence of adverse reactions was documented.

Results: After 12, 24, and 36 weeks of treatment, the HIV viral load in the DTG + 3TC group was consistently lower than that in the EFV + TDF + 3TC group (p < 0.05). At week 36 posttreatment, compared with the EFV + TDF + 3TC group, the DTG + 3TC group showed higher CD4⁺ counts and lower CD8⁺ counts (p < 0.05). Following treatment at week 36, levels of AST, ALT, TBiL, and PT were elevated in both groups but lower in the DTG + 3TC group (p < 0.05). The levels of ALB in both groups were decreased, but the DTG + 3TC group was significantly higher (p < 0.05). Additionally, at week 36 posttreatment, Scr levels were significantly better in the DTG + 3TC group compared to the EFV + TDF + 3TC group (p < 0.05). The incidence of adverse reactions in the DTG + 3TC group and EFV + TDF + 3TC group differed significantly, with rates of 13.33% and 23.33%, respectively (p > 0.05).

Conclusion: There is no difference in the safety of DTG + 3TC in the treatment of AIDS patients with ARL compared with TDF +3TC + EFV. However, the combination of DTG + 3TC simplified regimen is superior to the three-drug regimen of TDF + 3TC + EFV in reducing viral load and has positive effects on the improvement of liver function and blood creatinine, with no obvious side effects.